

*This document is an English-translated version of an attachment of notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Posaconazole

June 11, 2024

### **Therapeutic category**

Antibiotic preparations acting mainly on mold

### **Non-proprietary name**

Posaconazole

### **Safety measure**

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision						
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lurasidone hydrochloride, blonanserin, triazolam, rivaroxaban</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(NA)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, <u>finerenone</u>, lurasidone hydrochloride, blonanserin, triazolam, rivaroxaban</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td><u>Finerenone</u></td><td><u>The effect of finerenone may be enhanced.</u></td><td><u>The plasma concentration of finerenone is expected to rise due to the inhibition of CYP3A4 by co-administration with posaconazole.</u></td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Finerenone</u>	<u>The effect of finerenone may be enhanced.</u>	<u>The plasma concentration of finerenone is expected to rise due to the inhibition of CYP3A4 by co-administration with posaconazole.</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors					
<u>Finerenone</u>	<u>The effect of finerenone may be enhanced.</u>	<u>The plasma concentration of finerenone is expected to rise due to the inhibition of CYP3A4 by co-administration with posaconazole.</u>					

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.